Difference between revisions of "Actinium Ac 225 lintuzumab (Actimab-A)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Radioactive agents" to "Category:Radiotherapy medications") |
m |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Monoclonal antibody directed against CD33 with a radioactive agent attached. | Monoclonal antibody directed against CD33 with a radioactive agent attached. | ||
| − | =Preliminary data= | + | ==Preliminary data== |
| − | ==[[Acute myeloid leukemia]]== | + | ===[[Acute myeloid leukemia]]=== |
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Actimab-A | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | |||
[[Category:Radiotherapy medications]] | [[Category:Radiotherapy medications]] | ||
| − | [[Category:Anti-CD33 | + | [[Category:Anti-CD33 radioimmunoconjugates]] |
| − | [[Category:Acute myeloid leukemia medications]] | + | [[Category:Acute myeloid leukemia medications (investigational)]] |
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 21:05, 30 June 2023
Mechanism of action
Monoclonal antibody directed against CD33 with a radioactive agent attached.
Preliminary data
Acute myeloid leukemia
Also known as
- Brand name: Actimab-A